Itus Corp Cmn (ITUS) 4.00 $ITUS
ITUS Extends and Expands Collaborative Research Arrangement With The Wistar Institute
Marketwired - Mon Aug 15, 1:44PM CDT
LOS ANGELES, CA--(Marketwired - August 15, 2016) - ITUS Corporation (NASDAQ: ITUS) today announced that it has extended and expanded its collaboration with The Wistar Institute to further the development of Cchek™, the company's early cancer detection platform. The company is extending its existing arrangement with Wistar, and entering into a new collaboration with Dmitry I. Gabrilovich, M.D. Ph.D., a pioneer in the discovery and study of myeloid derived suppressor cells and the immune system response to cancer.
ITUS: 4.00 (-0.21)
ITUS Corporation (Nasdaq: ITUS) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Jun 02, 9:00AM CDT
What:
ITUS: 4.00 (-0.21), NDAQ: 71.24 (-0.10)
ITUS to Ring June 3, 2016 Nasdaq Closing Bell and Launch New Cancer Social Media Campaign
Marketwired - Tue May 31, 8:02AM CDT
LOS ANGELES, CA--(Marketwired - May 31, 2016) - ITUS Corporation (NASDAQ: ITUS) today announced that to commemorate National Cancer Survivor's Day on June 5, company representatives will ring the June 3, 2016 closing bell of The Nasdaq Stock Market. The occasion will also mark the official launch of a new cancer social media campaign entitled "Let's Get Crack'n Against Cancer."
ITUS: 4.00 (-0.21)
ITUS Featured on New York Radio Program
Marketwired - Thu Apr 28, 8:02AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, recently appeared on "Westchester On the Level with Narog and Aris," a news show broadcast by WHYT Radio. During the segment, Mr. Berman is interviewed by the show's host and Yonkers Tribune Editor, Hezi Aris.
ITUS: 4.00 (-0.21)
ITUS Featured on FOX News Health Segment
Marketwired - Mon Apr 25, 8:02AM CDT
ITUS Corporation ("ITUS" (NASDAQ: ITUS), today announced that its President and CEO, Robert Berman, recently appeared on a health segment on cancer for FOX News. During the segment, Mr. Berman is interviewed by Fox News Channel's Senior Managing Editor for Health News, Dr. Manny Alveraz.
ITUS: 4.00 (-0.21)
ITUS Subsidiary Anixa Diagnostics Corporation Demonstrates Efficacy of Early Cancer Detection Platform With Lung Cancer
Marketwire Canada - Tue Apr 19, 8:00AM CDT
ITUS Corporation ("ITUS" (NASDAQ: ITUS) today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has successfully demonstrated that its Ccheka"c early cancer detection platform can be used to identify the presence of lung cancer. The company will now expand its ongoing biomarker study to include additional lung cancer samples. Anixa previously announced results from the study with breast cancer patients.
ITUS: 4.00 (-0.21)
ITUS Featured on Several National and Local Radio Broadcasts
Marketwired - Thu Apr 14, 8:02AM CDT
ITUS Corporation ("ITUS" (NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, has recently appeared on several national and local radio broadcasts. Most recently, Mr. Berman appeared on NPR affiliate WFUV in New York. Last week, Mr. Berman was an hour-long guest on Joni Aldrich SOS, the iHeartRadio show hosted by nationally acclaimed cancer advocate Joni Aldrich.
ITUS: 4.00 (-0.21)
American Cancer Society Vice Chairman of the National Board of Directors, Dr. Arnold Baskies, Joins Scientific Advisory Board for ITUS Subsidiary Anixa Diagnostics Corporation
Marketwired - Mon Jan 25, 8:01AM CST
ITUS Corporation ("ITUS" (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Arnold Baskies, the Vice Chairman of the Board of Directors of the American Cancer Society, to its Scientific Advisory Board. Dr. Baskies previously served as Chief Science Officer to the Board of Directors of the American Cancer Society and as President of the American Cancer Society of New York and New Jersey. He has been appointed by every New Jersey governor through 2015 to serve as Chair of the New Jersey Governor's Task Force on Cancer Prevention, Early Detection & Treatment.
ITUS: 4.00 (-0.21)
ITUS Subsidiary Anixa Diagnostics Corporation Appoints Dr. Michael Shepard to Its Scientific Advisory Board
Marketwired - Mon Dec 07, 8:01AM CST
ITUS Corporation ("ITUS" (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Michael Shepard to its Scientific Advisory Board. Dr. Shepard is a pioneer in modern cancer research, whose many successes include work that lead to the discovery, development and launch of Herceptin, one of the best-selling cancer drugs of all time, used to treat breast cancer. Cumulative Herceptin sales have totaled more than $50 Billion, including sales in 2014 of greater than $7 Billion. Herceptin's approval opened the door for many other antibody therapies for cancer. For his work in this field, Dr. Shepard received the very prestigious Warren Alpert Prize, an annual award granted by The Warren Alpert Foundation, in association with Harvard Medical School, to scientists, physicians, and researchers, whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease.
ITUS: 4.00 (-0.21)
ITUS Subsidiary Anixa Diagnostics Corporation Announces Initial Cancer Biomarker Results
Marketwired - Mon Oct 05, 8:02AM CDT
ITUS Corporation ("ITUS" (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, in collaboration with The Wistar Institute, a National Cancer Institute-designated Cancer Center, has achieved very favorable initial results in a cancer biomarker study, successfully demonstrating the efficacy of Anixa's cancer screening technology. Wistar evaluated blood samples from a small group of patients with differing severities of breast cancer to determine the presence or absence of unique and anomalous biomarkers. Wistar also studied blood samples from a small group of healthy patients. The initial results showed the presence of the biomarkers in 100% of the cancer patients tested. Equally as important, none of the healthy patient blood samples contained the biomarkers.
ITUS: 4.00 (-0.21)
ITUS Subsidiary Auction Acceleration Corporation Enters Into Settlement and License Agreement With eBay, Vendio, & Auctiva
Marketwired - Wed Jul 15, 6:00AM CDT
ITUS Corporation ("ITUS" (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Auction Acceleration Corporation ("AAC", has entered into a Settlement and License Agreement with eBay, Inc., Auctiva, LLC, and Vendio Services, LLC.
ITUS: 4.00 (-0.21), EBAY: 32.09 (+0.32)
ITUS Subsidiary Anixa Diagnostics Enters Into Collaborative Research Agreement With The Wistar Institute, a Leading Cancer Research Institute
Marketwired - Tue Jul 14, 11:52AM CDT
ITUS Corporation ("ITUS" (NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has entered into a Collaborative Research Agreement with The Wistar Institute, located on the campus of the University of Pennsylvania in Philadelphia, Pennsylvania, to further the development of a cancer screening test. Founded in 1892 as the nation's first independent biomedical research institute, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI's select network of national cancer research centers, holding an 'Exceptional' rating -- the highest possible ranking awarded.
ITUS: 4.00 (-0.21)
ITUS Extends and Expands Collaborative Research Arrangement With The Wistar Institute
Marketwired - Mon Aug 15, 1:44PM CDT
LOS ANGELES, CA--(Marketwired - August 15, 2016) - ITUS Corporation (NASDAQ: ITUS) today announced that it has extended and expanded its collaboration with The Wistar Institute to further the development of Cchek™, the company's early cancer detection platform. The company is extending its existing arrangement with Wistar, and entering into a new collaboration with Dmitry I. Gabrilovich, M.D. Ph.D., a pioneer in the discovery and study of myeloid derived suppressor cells and the immune system response to cancer.
ITUS: 4.00 (-0.21)
ITUS Corporation (Nasdaq: ITUS) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Jun 02, 9:00AM CDT
What:
ITUS: 4.00 (-0.21), NDAQ: 71.24 (-0.10)
ITUS to Ring June 3, 2016 Nasdaq Closing Bell and Launch New Cancer Social Media Campaign
Marketwired - Tue May 31, 8:02AM CDT
LOS ANGELES, CA--(Marketwired - May 31, 2016) - ITUS Corporation (NASDAQ: ITUS) today announced that to commemorate National Cancer Survivor's Day on June 5, company representatives will ring the June 3, 2016 closing bell of The Nasdaq Stock Market. The occasion will also mark the official launch of a new cancer social media campaign entitled "Let's Get Crack'n Against Cancer."
ITUS: 4.00 (-0.21)
ITUS Featured on New York Radio Program
Marketwired - Thu Apr 28, 8:02AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, recently appeared on "Westchester On the Level with Narog and Aris," a news show broadcast by WHYT Radio. During the segment, Mr. Berman is interviewed by the show's host and Yonkers Tribune Editor, Hezi Aris. ITUS: 4.00 (-0.21)
ITUS Featured on FOX News Health Segment
Marketwired - Mon Apr 25, 8:02AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS), today announced that its President and CEO, Robert Berman, recently appeared on a health segment on cancer for FOX News. During the segment, Mr. Berman is interviewed by Fox News Channel's Senior Managing Editor for Health News, Dr. Manny Alveraz. ITUS: 4.00 (-0.21)
ITUS Subsidiary Anixa Diagnostics Corporation Demonstrates Efficacy of Early Cancer Detection Platform With Lung Cancer
Marketwire Canada - Tue Apr 19, 8:00AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS) today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has successfully demonstrated that its Ccheka"c early cancer detection platform can be used to identify the presence of lung cancer. The company will now expand its ongoing biomarker study to include additional lung cancer samples. Anixa previously announced results from the study with breast cancer patients. ITUS: 4.00 (-0.21)
ITUS Featured on Several National and Local Radio Broadcasts
Marketwired - Thu Apr 14, 8:02AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS) today announced that its President and CEO, Robert Berman, has recently appeared on several national and local radio broadcasts. Most recently, Mr. Berman appeared on NPR affiliate WFUV in New York. Last week, Mr. Berman was an hour-long guest on Joni Aldrich SOS, the iHeartRadio show hosted by nationally acclaimed cancer advocate Joni Aldrich. ITUS: 4.00 (-0.21)
American Cancer Society Vice Chairman of the National Board of Directors, Dr. Arnold Baskies, Joins Scientific Advisory Board for ITUS Subsidiary Anixa Diagnostics Corporation
Marketwired - Mon Jan 25, 8:01AM CST
ITUS Corporation ("ITUS"
(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Arnold Baskies, the Vice Chairman of the Board of Directors of the American Cancer Society, to its Scientific Advisory Board. Dr. Baskies previously served as Chief Science Officer to the Board of Directors of the American Cancer Society and as President of the American Cancer Society of New York and New Jersey. He has been appointed by every New Jersey governor through 2015 to serve as Chair of the New Jersey Governor's Task Force on Cancer Prevention, Early Detection & Treatment. ITUS: 4.00 (-0.21)
ITUS Subsidiary Anixa Diagnostics Corporation Appoints Dr. Michael Shepard to Its Scientific Advisory Board
Marketwired - Mon Dec 07, 8:01AM CST
ITUS Corporation ("ITUS"
(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has added Dr. Michael Shepard to its Scientific Advisory Board. Dr. Shepard is a pioneer in modern cancer research, whose many successes include work that lead to the discovery, development and launch of Herceptin, one of the best-selling cancer drugs of all time, used to treat breast cancer. Cumulative Herceptin sales have totaled more than $50 Billion, including sales in 2014 of greater than $7 Billion. Herceptin's approval opened the door for many other antibody therapies for cancer. For his work in this field, Dr. Shepard received the very prestigious Warren Alpert Prize, an annual award granted by The Warren Alpert Foundation, in association with Harvard Medical School, to scientists, physicians, and researchers, whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease. ITUS: 4.00 (-0.21)
ITUS Subsidiary Anixa Diagnostics Corporation Announces Initial Cancer Biomarker Results
Marketwired - Mon Oct 05, 8:02AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, in collaboration with The Wistar Institute, a National Cancer Institute-designated Cancer Center, has achieved very favorable initial results in a cancer biomarker study, successfully demonstrating the efficacy of Anixa's cancer screening technology. Wistar evaluated blood samples from a small group of patients with differing severities of breast cancer to determine the presence or absence of unique and anomalous biomarkers. Wistar also studied blood samples from a small group of healthy patients. The initial results showed the presence of the biomarkers in 100% of the cancer patients tested. Equally as important, none of the healthy patient blood samples contained the biomarkers. ITUS: 4.00 (-0.21)
ITUS Subsidiary Auction Acceleration Corporation Enters Into Settlement and License Agreement With eBay, Vendio, & Auctiva
Marketwired - Wed Jul 15, 6:00AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Auction Acceleration Corporation ("AAC", has entered into a Settlement and License Agreement with eBay, Inc., Auctiva, LLC, and Vendio Services, LLC. ITUS: 4.00 (-0.21), EBAY: 32.09 (+0.32)
ITUS Subsidiary Anixa Diagnostics Enters Into Collaborative Research Agreement With The Wistar Institute, a Leading Cancer Research Institute
Marketwired - Tue Jul 14, 11:52AM CDT
ITUS Corporation ("ITUS"
(NASDAQ: ITUS), today announced that its wholly owned subsidiary, Anixa Diagnostics Corporation, has entered into a Collaborative Research Agreement with The Wistar Institute, located on the campus of the University of Pennsylvania in Philadelphia, Pennsylvania, to further the development of a cancer screening test. Founded in 1892 as the nation's first independent biomedical research institute, Wistar is an international leader in the biomedical research fields of cancer, immunology and infectious diseases, a National Cancer Institute (NCI)-designated Cancer Center, and part of the NCI's select network of national cancer research centers, holding an 'Exceptional' rating -- the highest possible ranking awarded. ITUS: 4.00 (-0.21)
